Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Wacheck

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Optics Letters|May 16, 2003
Compact, broad-bandwidth fiber laser for sub-2-microm axial resolution optical coherence tomography in the 1300-nm wavelength regionK Bizheva, B Povazay, B Hermann, et al.
European Journal of Clinical Investigation|June 20, 2007
A clinical trial on absorption and N-acetylation of oral and rectal mesalazineK Dilger, D Trenk, M Rössle, et al.
Lancet (London, England)|November 30, 2000
Chemosensitisation of malignant melanoma by BCL2 antisense therapyB Jansen, V Wacheck, E Heere-Ress, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2024
Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profilingL Goyal, D DiToro, A Hollebecque, et al.
European Journal of Clinical Investigation|December 22, 2006
Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cellsA W Hauswirth, S Florian, D Printz, et al.
British Journal of Cancer|May 14, 2009
FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivoD Cejka, C Kuntner, M Preusser, et al.
Melanoma Research|August 2, 2001
Differential expression levels of Par-4 in melanomaT Lucas, B Pratscher, S Krishnan, et al.
ESMO Open|December 31, 2025
A phase II study of the AKT inhibitor TAS-117 in patients with advanced solid tumors and germline PTEN mutationsJ Ródon, H-T Arkenau, P Funchain, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Optics Letters|May 16, 2003
Compact, broad-bandwidth fiber laser for sub-2-microm axial resolution optical coherence tomography in the 1300-nm wavelength regionK Bizheva, B Povazay, B Hermann, et al.
European Journal of Clinical Investigation|June 20, 2007
A clinical trial on absorption and N-acetylation of oral and rectal mesalazineK Dilger, D Trenk, M Rössle, et al.
Lancet (London, England)|November 30, 2000
Chemosensitisation of malignant melanoma by BCL2 antisense therapyB Jansen, V Wacheck, E Heere-Ress, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2024
Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profilingL Goyal, D DiToro, A Hollebecque, et al.
European Journal of Clinical Investigation|December 22, 2006
Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cellsA W Hauswirth, S Florian, D Printz, et al.
British Journal of Cancer|May 14, 2009
FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivoD Cejka, C Kuntner, M Preusser, et al.
Melanoma Research|August 2, 2001
Differential expression levels of Par-4 in melanomaT Lucas, B Pratscher, S Krishnan, et al.
ESMO Open|December 31, 2025
A phase II study of the AKT inhibitor TAS-117 in patients with advanced solid tumors and germline PTEN mutationsJ Ródon, H-T Arkenau, P Funchain, et al.
Pageof 2